Literature DB >> 22955209

Fab-arm exchange: what's in a name?

Janine Schuurman, Aran F Labrijn, Paul W H I Parren.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955209      PMCID: PMC3502229          DOI: 10.4161/mabs.22075

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


× No keyword cloud information.
Immunology and structural biology are highly complex fields of study in which mechanisms and inter-relationships are often not easily understood. It is therefore quite common to use metaphors to make knowledge gained accessible to experts and non-experts alike. Thus we, for example, all know the antibody as a Y-shaped protein with two arms and a tail and we understand the specificity of antibody-antigen binding as a key-into-lock interaction. Are these metaphors strictly correct? No, of course not. Nevertheless, they are well-recognized and serve to provide some immediate and general understanding of key features. When faced with the challenge of designing a simple descriptor or metaphor for the process leading to the exchange of human IgG4 “half-molecules,” we discussed various options with experts in the field and came up with the term “Fab-arm exchange.” The phrase is simply meant to highlight the functional consequence of this mechanism, i.e., the exchange of antigen-binding parts between parental antibody molecules leading to novel binding combinations in the product. Professor Pandey argues in his letter that Fab-arm exchange is a misnomer and should be changed to IgG4-arm exchange with the argument that allotypic differences are ignored. Apart from the fact that, seen from Pandey’s view, the phrase IgG4-arm exchange suffers from similar weaknesses as the original (and should be termed IgG4-arm-and-tail exchange instead), clearly we disagree. This is not only in view of the above, but also due to the observation that Fab-arm exchange occurs in many animals involving distinct non-IgG4 antibody subclasses.- In addition, we are obliged to point out that Pandey uses a weak example. Neither the V309/L309 nor the K409/R409 isoallotype are likely to have a functional impact on the product. Thus, we have demonstrated in Labrijn et al., that K409 abrogates Fab-arm exchange for human IgG4 molecules and the exchange between isoallotypes in individuals carrying both genes therefore cannot occur. The formation of V309-L309 IgG4 heterodimers, in our view, has limited relevance as there is no indication in the literature that the isoallotype at this position affects antibody function. In fact, Pandey might have found a better argument outside of the field of IgG allotypes. Differences in Fc-associated carbohydrates, for example, may affect antibody effector function or half-life, and this therefore represents an example where the exchange of (half) Fc domains between antibody molecules might affect activity of the product. Nevertheless, we also believe that such exchange will not have significant functional consequences in a polyclonal response in vivo because of the dynamic recombination of these modifications with random antigen-binding specificities. In summary, the reassortment of antigen-binding specificities is the major functional consequence of Fab-arm exchange and that’s in the name.
  8 in total

1.  Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.

Authors:  Marijn van der Neut Kolfschoten; Janine Schuurman; Mario Losen; Wim K Bleeker; Pilar Martínez-Martínez; Ellen Vermeulen; Tamara H den Bleker; Luus Wiegman; Tom Vink; Lucien A Aarden; Marc H De Baets; Jan G J van de Winkel; Rob C Aalberse; Paul W H I Parren
Journal:  Science       Date:  2007-09-14       Impact factor: 47.728

2.  Molecular characterization of immunoglobulin G4 gene isoallotypes.

Authors:  A Brusco; S Saviozzi; F Cinque; M DeMarchi; C Boccazzi; G de Lange; A M van Leeuwen; A O Carbonara
Journal:  Eur J Immunogenet       Date:  1998-10

Review 3.  Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics.

Authors:  Daniela Bumbaca; C Andrew Boswell; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-18       Impact factor: 4.009

4.  Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.

Authors:  Aran F Labrijn; Theo Rispens; Joyce Meesters; Rebecca J Rose; Tamara H den Bleker; Stefan Loverix; Ewald T J van den Bremer; Joost Neijssen; Tom Vink; Ignace Lasters; Rob C Aalberse; Albert J R Heck; Jan G J van de Winkel; Janine Schuurman; Paul W H I Parren
Journal:  J Immunol       Date:  2011-08-12       Impact factor: 5.422

5.  Production of native bispecific antibodies in rabbits.

Authors:  Wei Wang; Ruihuan Xu; Jinming Li
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

6.  Comparison of the ability of wild type and stabilized human IgG(4) to undergo Fab arm exchange with endogenous IgG(4)in vitro and in vivo.

Authors:  Kenneth B Lewis; Brent Meengs; Kent Bondensgaard; Lay Chin; Steven D Hughes; Birgitte Kjaer; Søren Lund; Liping Wang
Journal:  Mol Immunol       Date:  2009-08-14       Impact factor: 4.407

Review 7.  Glycosylation as a strategy to improve antibody-based therapeutics.

Authors:  Roy Jefferis
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

8.  Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes.

Authors:  Janardan P Pandey
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

  8 in total
  2 in total

1.  Estimation of polyclonal IgG4 hybrids in normal human serum.

Authors:  Elizabeth Young; Emma Lock; Douglas G Ward; Alexander Cook; Stephen Harding; Gregg L F Wallis
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 2.  Opening the door to innovation.

Authors:  Janine Schuurman; Yvo F Graus; Aran F Labrijn; Sigrid Ruuls; Paul W H I Parren
Journal:  MAbs       Date:  2014-04-24       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.